Document is current

Article History

Accepted: 9 July 2024

First Online: 1 August 2024

Declarations

:

: D. Ochoa, M Román, S. Martin Vilchez, and S. Luquero-Bueno have been a consultant or investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Aptatargets, Chemo, FAES, Farmalíder, Ferrer, Galenicum, GlaxoSmithKline, Gilead, Italfarmaco, Janssen-Cilag, Kern, Normon, Novartis, Servier, Teva, and Zambon. C. Sánchez, I. Gilaberte, and P. Arranz are full-time employees of FAES FARMA.

: Carla Granados from Trialance SCCL provided medical writing assistance supported by FAES FARMA according to Good Publication Practice guidelines.

: This work was funded by FAES FARMA (Leioa, Spain)

: The data that support the findings of this study are available on request from the corresponding author.

: The study was conducted at Hospital Universitario de La Princesa (Madrid, Spain) after receiving approval from the Ethics Committee of the hospital and the Spanish Agency of Medicines and Medical Devices (AEMPS), and was conducted in accordance with the ethical principles based on the Declaration of Helsinki of 1964 and its later amendments.

: All participants provided written informed consent.

: No identifying data of study subjects were used. All subjects were informed via the informed consent form about the potential publication of study results, ensuring that their identities were not disclosed.

: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Manuel Román, Dolores Ochoa, Samuel Martin, and Sergio Luquero. The first draft of the manuscript was written by Carlos Sánchez and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.